| payload |
{"created_at":"2026-04-21T03:09:54.871 {"created_at":"2026-04-21T03:09:54.871544+00:00","dedupe_key":"signal_enriched:discovery_sec_filing_delta:defe64f57be94efd","evidence_event_ids":["evt_7569e9d9d223"],"signal_type":"discovery_sec_filing_delta","source":"discovery_sec_filings","value":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/101538/0001140361-26-015650.txt","as_of":"2026-04-21T03:09:54.871544+00:00","canonical_url":"https://www.sec.gov/Archives/edgar/data/101538/0001140361-26-015650.txt","company":"UNITED STATES ANTIMONY CORP","enrichment":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/101538/0001140361-26-015650.txt","article_chars":5000,"article_truncated":true,"blocked_reason":null,"candidate_id":"sc_ff173b7bcbf5a076","canonical_host":"sec.gov","canonical_is_aggregator":false,"canonical_url":"https://www.sec.gov/Archives/edgar/data/101538/0001140361-26-015650.txt","content_type":"text/plain","enriched_at":"2026-04-21T06:46:14.732172+00:00","extraction_method":"trafilatura","fetched_description":"","fetched_title":"","final_url":"https://www.sec.gov/Archives/edgar/data/101538/0001140361-26-015650.txt","html_truncated":true,"paywall_likely":false,"publisher_domain":"sec.gov","publisher_resolution":"canonical_url","requested_url":"https://www.sec.gov/Archives/edgar/data/101538/0001140361-26-015650.txt","source_event_id":"evt_7569e9d9d223","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"form_type":"DEF 14A","fp":"59e4bcf72cadccdb","kind":"sec_filing","published_at":"20260420","publisher_domain":"sec.gov","signal_understanding":{"analysis_basis":"article","claim_confidence":0.74,"dates_mentioned":["2026-04-21","February 2021","March 2024","November 2024","December 2024","July 15, 2015","2010","February 2021","October 14, 2019","August 2019","February 2024","May 2007","November 2013","2006","2005","2003","1989","1991","1994","December 2003","2018","2022"],"entities":[{"asset_class":"equity","name":"UNITED STATES ANTIMONY CORP","relevance":"high","symbol":"UAMY","type":"issuer"},{"asset_class":"person","name":"Lloyd Joseph Bardswich","relevance":"medium","symbol":"","type":"person"},{"asset_class":"person","name":"Dr. Blaise Aguirre","relevance":"medium","symbol":"","type":"person"},{"asset_class":"person","name":"Joseph A. Carrabba","relevance":"medium","symbol":"","type":"person"},{"asset_class":"person","name":"General (Ret.) John M. (\u201cJack\u201d) Keane","relevance":"medium","symbol":"","type":"person"}],"event_type":"listing","information_gaps":["The excerpt does not state the proxy agenda items (e.g., election of directors, proposals, voting matters) or any changes vs a prior DEF 14A state.","No explicit financial guidance, earnings figures, or compensation numbers are included in the provided text.","The excerpt contains unrelated content about Novavax (Vaccine Nuvaxovid\u2122) and NVAX market capitalization; it is unclear how (or whether) this relates to the issuer\u2019s DEF 14A content.","No explicit statement of what changed compared to prior known state is provided in the supplied text (no prior filing text/delta is included).","The provided context includes a filing date of 2026-04-21, while the headline/source summary mentions 20260420; the discrepancy is not resolved in the excerpt."],"key_facts":["Form type: DEF 14A.","Issuer: UNITED STATES ANTIMONY CORP.","Filing date (from provided context): 2026-04-21T03:09:54.871544+00:00.","The excerpt includes director biography sections for Lloyd Joseph Bardswich, Dr. Blaise Aguirre, Joseph A. Carrabba, and General (Ret.) John M. (\u201cJack\u201d) Keane.","The excerpt includes biographical details such as prior roles and dates (e.g., Bardswich joined the board in February 2021; Carrabba joined in February 2024; Aguirre joined in August 2019)."],"numeric_claims":[{"label":"Filing date (UTC)","value":"2026-04-21T03:09:54.871544+00:00"},{"label":"Bardswich board join month/year","value":"February 2021"},{"label":"Bardswich EVP/director since","value":"December 2024"},{"label":"Bardswich served as Co-CEO and director from","value":"March 2024"},{"label":"Bardswich served as Co-CEO and director to","value":"November 2024"},{"label":"Aguirre board join month/year","value":"August 2019"},{"label":"Carrabba board join month/year","value":"February 2024"},{"label":"Keane completed public service in","value":"December 2003"}],"primary_claim":"UNITED STATES ANTIMONY CORP filed Form DEF 14A (proxy statement) on 2026-04-21.","relevance_score":0.62,"sentiment":"neutral","source_quality":"high","summary":"United States Antimony Corp (UAMY) filed a DEF 14A proxy statement on 2026-04-21. The provided text excerpt contains biographical details for several directors and does not include specific proxy agenda items or financial guidance.","topics":["SEC filing","DEF 14A","proxy statement","board of directors","director biographies"]},"source":"sec_edgar","source_domain":"sec.gov","summary":"Form DEF 14A \u00b7 UNITED STATES ANTIMONY CORP \u00b7 Filed 20260420","ticker":"UAMY","tickers":["UAMY"],"title":"UAMY filed DEF 14A","url":"https://www.sec.gov/Archives/edgar/data/101538/0001140361-26-015650.txt"}}... |